《生物安全法案》复盘 --如何看待地缘政治对中国CXO企业的影响？ 行业研究 · 行业专题 医药生物 · 医疗研发外包 投资评级：优于大市（维持评级） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 请务必阅读正文之后的免责声明及其项下所有内容 1 报告摘要 证券研究报告 | 2025年12月28日 n 靴子落地，美国《2026财年国防授权法案》夹带《生物安全法案》生效。 请务必阅读正文之后的免责声明及其项下所有内容 2 ü 《2026财年国防授权法案》夹带《生物安全法案》（主要指第851节《禁止与特定生物技术公司签订合同》）落地，标志着美国已将生物安全正式纳入国家防务与 安全战略框架统筹考量，同时彰显其在生物技术供应链自主可控的明确政策转向，本质是中美的科技竞争与产业安全博弈在生物领域的延 ...

Core Viewpoint - The "Quality Return Dual Improvement" initiative launched by the Shenzhen Stock Exchange aims to enhance the development quality and investment value return capabilities of listed companies, with 471 companies disclosing action plans by November 2025 [1][2]. Group 1: Company Participation and Focus Areas - Among the 471 companies, 293 are part of the Shenzhen Component Index, 88 are in the CSI 300 Index, and 82 belong to the ChiNext Index, collectively representing about 50% of the total market capitalization of the Shenzhen market [2]. - The companies involved span 30 industries, including electronics, power equipment, pharmaceuticals, and computers, with nearly 70% being private enterprises [2]. - The action plans of these companies emphasize three focal points: focusing on core business, focusing on technological innovation, and focusing on regulatory operations [2]. Group 2: Financial Performance and R&D Investment - In 2024, the "Dual Improvement" companies achieved a total operating revenue of 9.8 trillion yuan, a year-on-year increase of 3.6%, and a net profit of 743.39 billion yuan [4]. - For the first three quarters of 2025, these companies reported an operating revenue of 7.5 trillion yuan, up 6.9% year-on-year, and a net profit of 651.3 billion yuan, reflecting a 10.8% increase [4]. - The R&D investment of these companies accounted for 4.3% of their operating revenue in the first half of 2025, up 0.1 percentage points year-on-year, with total R&D expenditure representing 59.5% of the Shenzhen market [4]. Group 3: Shareholder Returns and Market Response - From 2022 to 2024, the annual total dividend of the "Dual Improvement" companies had a compound growth rate of 10.0%, with the 2024 dividend amounting to 43.6% of net profit, an increase of 10.9 percentage points from 2022 [5]. - Approximately 80% of the companies (378) maintained continuous dividends over the past three years, enhancing the stability and predictability of returns for investors [5]. - The average stock price increase for the 471 "Dual Improvement" companies from February 2024 to November 2025 was 77.2%, surpassing the growth of the Shenzhen Component Index [6].

Core Insights - The "Quality Return Dual Improvement" initiative launched by the Shenzhen Stock Exchange aims to enhance the development quality and investment value return capabilities of listed companies, with 471 companies having disclosed action plans by November 2025 [1][2] Group 1: Company Participation and Industry Coverage - Among the 471 companies, 293 are part of the Shenzhen Component Index, 88 are in the CSI 300 Index, and 82 belong to the ChiNext Index, collectively representing about 50% of the total market capitalization of Shenzhen [2] - The participating companies span 30 industries, including electronics, power equipment, pharmaceuticals, and computers, with a significant presence of private enterprises, accounting for nearly 70% of the participants [2] Group 2: Focus Areas of Improvement - The action plans from the listed companies emphasize three main focuses: enhancing core business awareness, improving technological innovation capabilities, and strengthening regulatory operations [2] - Specific examples include Mindray Medical (300760.SZ) increasing R&D investment and global expansion, and BYD (002594.SZ) planning R&D expenditures of 54.2 billion yuan in 2024 [2] Group 3: Shareholder Returns and Buybacks - Companies are increasing dividend and buyback efforts, with firms like BOE Technology Group (000725.SZ) disclosing future shareholder return plans, and Anke Bio (300009.SZ) maintaining 16 consecutive years of cash dividends [3] - The average annual dividend growth rate for "dual improvement" companies from 2022 to 2024 is 10.0%, with 2024 dividends accounting for 43.6% of net profits, a 10.9 percentage point increase from 2022 [5] Group 4: Financial Performance and Market Response - In terms of financial performance, "dual improvement" companies achieved a total revenue of 9.8 trillion yuan in 2024, a 3.6% year-on-year increase, and a net profit of 743.39 billion yuan [4] - The average stock price increase for these companies from February 2024 to November 2025 was 77.2%, surpassing the Shenzhen Component Index, with a total market capitalization of 21.2 trillion yuan by November 2025 [6]

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric (00042), Zhejiang Shibao (01057), and Junda Co. (02865) leading in premium rates, while CATL (03750), China Merchants Bank (03968), and Hansoh Pharmaceutical (01276) are at the bottom of the list [1]. Premium Rate Summary - Northeast Electric (00042) has a premium rate of 900.00% with an H-share price of 0.270 HKD and an A-share price of 2.25 CNY [1]. - Zhejiang Shibao (01057) shows a premium rate of 472.95% with H-share at 4.880 HKD and A-share at 23.34 CNY [1]. - Junda Co. (02865) has a premium rate of 286.59% with H-share priced at 17.000 HKD and A-share at 54.87 CNY [1]. - CATL (03750) has a negative premium rate of -11.39% with H-share at 508.500 HKD and A-share at 376.18 CNY [1]. - China Merchants Bank (03968) has a premium rate of -3.20% with H-share at 51.600 HKD and A-share at 41.7 CNY [1]. Deviation Value Summary - Zhejiang Shibao (01057) leads in deviation value at 187.01% [1]. - Junda Co. (02865) follows with a deviation value of 94.84% [1]. - Nanjing Panda Electronics (00553) has a deviation value of 36.09% [1]. - GAC Group (02238) has the lowest deviation value at -22.30% [1]. - Changfei Optical Fiber (06869) has a deviation value of -19.89% [1]. Additional Insights - The report includes a detailed table of the top ten and bottom ten AH shares based on premium rates and deviation values, providing a comprehensive overview of the current market situation [2][3].

Core Viewpoint - Peptone is widely used as a major nutrient component in culture media, promoting cell proliferation and production, with its raw materials including meat, casein, whey, gelatin, soy, yeast, and grains [2][4]. Summary by Sections 1. Peptone Market Overview - The Chinese peptone market is projected to reach 411 million yuan in 2024 and 620 million yuan by 2031, with a compound annual growth rate (CAGR) of 4.98% [4]. - Peptone serves as an important nitrogen source in microbial culture, with applications in antibiotics, vaccines, recombinant proteins, and fermentation products [8]. 2. Peptone Classification and Characteristics - Peptone is categorized into three types: animal peptone, plant peptone, and yeast peptone, each with unique properties based on the source and quality of the starting protein material [3][8]. - Animal peptone accounts for 37.01% of total consumption in 2024, with challenges in availability, cost fluctuations, and animal-source risks leading to a relative decline in demand [9]. 3. Industry Concentration Analysis - The Chinese peptone market is highly concentrated, with the top five suppliers accounting for 62.05% of sales in 2024. Angel Yeast is the largest supplier, offering a range of products across various applications [10]. 4. Peptone Industry Chain Analysis - The upstream of the peptone industry includes raw materials such as meat, casein, whey, gelatin, soy, yeast, and grains, with animal peptone being the most widely used [15][16]. - The midstream consists of manufacturing enterprises that prepare nitrogen sources from different origins, with a notable reliance on imported high-end peptone technologies [19][20]. 5. Downstream Applications - Downstream applications of peptone are concentrated in pharmaceuticals, food, cosmetics, and research, with high-end pharmaceutical companies requiring high quality and batch consistency [21]. - The market shows a diverse landscape with high-value products and a focus on process stability, indicating a robust demand across various sectors [21].

Group 1 - The core initiative of the Shenzhen Stock Exchange is the "Quality Return Dual Improvement" action, aimed at enhancing the development quality and investment value return capabilities of listed companies, with 471 companies already disclosing their action plans by November 2025 [1] - The 471 companies involved have significant influence, with 293 being part of the Shenzhen Component Index, 88 in the CSI 300 Index, and 82 in the ChiNext Index, collectively representing about 50% of the total market capitalization of the Shenzhen market [1] - The participating companies span 30 industries, including electronics, power equipment, pharmaceuticals, and computers, with nearly 70% being private enterprises [1] Group 2 - The "Dual Improvement" companies have focused on core business development, achieving a total operating revenue of 9.8 trillion yuan in 2024, a year-on-year increase of 3.6%, and a net profit of 743.39 billion yuan [2] - In the first three quarters of 2025, these companies reported an operating revenue of 7.5 trillion yuan, up 6.9% year-on-year, and a net profit of 651.3 billion yuan, reflecting a 10.8% increase [2] - Research and development (R&D) investment accounted for 4.3% of operating revenue in the first half of 2025, with a total R&D investment representing 59.5% of the Shenzhen market [2] Group 3 - From 2022 to 2024, the annual total dividend of the "Dual Improvement" companies grew at a compound annual growth rate of 10%, with the 2024 dividend amount accounting for 43.6% of net profit, an increase of 10.9 percentage points from 2022 [3] - In 2024, the dividend amount represented 60.8% of the total dividends in the Shenzhen market, up 3.7 percentage points from 2022, indicating a steady growth in dividend amounts and proportions [3] - A total of 378 companies maintained continuous dividends over the past three years, enhancing dividend stability and predictability, while 203 share repurchase plans were disclosed, including a nearly 1 billion yuan repurchase by Kailaiying [3]

深交所"质量回报双提升"专项行动取得阶段性积极成果。 数据显示，从2024年2月行动启动以来，截至2025年11月底，已有471家深市上市公司主动披露了行动方 案，通过聚焦主业、创新、治理及强化投资者回报等务实举措，显著夯实了发展根基，增强了市场信心 与投资价值，发挥了重要的市场示范与引领作用。 2024年2月至2025年11月，471家公司股价平均涨幅达77.2%，显著跑赢深证成指。期间其总市值增长8.1 万亿元，百亿、千亿市值公司数量较行动前分别增加80家和21家。 一是聚焦主业发展。相关公司通过技术升级与国际化拓展巩固核心竞争力。例如，迈瑞医疗（300760） 持续高强度研发投入推动产品高端化、智能化；胜宏科技（300476）通过跨境并购增强了在全球柔性电 路板领域的竞争力，2024年海外收入占比超60%。 二是聚焦科技创新。相关公司持续加大研发投入并加速成果转化。比亚迪（002594）2024年研发支出高 达542亿元；广立微（301095）同期研发投入占营业收入比重超50%。中信特钢（000708）、TCL中环 （002129）等公司在知识产权布局上成果丰硕。 三是聚焦规范运作。通过完善公司治理、提 ...

Group 1 - The core initiative "Quality Return Dual Improvement" launched by the Shenzhen Stock Exchange aims to enhance the development quality and investment value return capability of listed companies, with 471 companies already disclosing their action plans by November 2025 [1] - These 471 companies represent significant market influence, with 293 being part of the Shenzhen Component Index and 88 part of the CSI 300 Index, collectively accounting for approximately 50% of the total market capitalization of the Shenzhen market [1] - The initiative has seen active participation from private enterprises, which make up nearly 70% of the companies involved, demonstrating a strong commitment to quality and return [1] Group 2 - Companies are focusing on core business development, with examples like Mindray Medical investing heavily in R&D for product upgrades and Shenghong Technology enhancing global competitiveness through acquisitions [2] - There is a strong emphasis on technological innovation, with BYD's R&D expenditure reaching 54.2 billion yuan in 2024, and Guoli Micro's R&D investment exceeding 50% of its revenue [2] - Companies are also improving governance and information disclosure, with Anker Innovations enhancing its governance structure and Xiandai Intelligent increasing the transparency of its disclosures [2] Group 3 - Companies are increasing their dividend and share repurchase efforts, with BOE Technology Group and others disclosing future shareholder return plans, and Anke Bio achieving a cumulative dividend amounting to 63% of its net profit since listing [3] - Key stakeholders are actively increasing their holdings, with major shareholders of GoerTek purchasing 47.44 million shares for approximately 1 billion yuan, reflecting confidence in the company's value [3] - Companies are enhancing communication with investors through various channels, with ZTE maintaining regular contact and providing updates on financial performance [3] Group 4 - ESG practices are being integrated into business strategies, with Longyuan Power linking ESG performance to management incentives and continuously upgrading its ESG disclosure systems [4] - The overall quality of companies is improving, with the "dual improvement" companies achieving a total revenue of 9.8 trillion yuan in 2024, a 3.6% increase year-on-year, and a net profit of 743.39 billion yuan [4] - In the first three quarters of 2025, these companies reported a revenue of 7.5 trillion yuan, reflecting a 6.9% year-on-year growth [4] Group 5 - R&D investment among "dual improvement" companies accounted for 4.3% of their revenue in the first half of 2025, with a total R&D expenditure representing 59.5% of the Shenzhen market [5] - The number of R&D personnel increased by 4.6% in 2024, averaging 1,944 employees, which constitutes 19.4% of the workforce [5] - The effectiveness of information disclosure has improved, with 58.6% of "dual improvement" companies receiving an A rating in 2024, an increase of 11.3 percentage points from before the initiative [5] Group 6 - The level of returns to investors has significantly increased, with a compound annual growth rate of 10.0% in total dividends from 2022 to 2024, and dividends in 2024 accounting for 43.6% of net profits [6] - Approximately 80% of the companies have maintained consistent dividends over the past three years, enhancing market confidence [6] - The average number of investor engagements per company was 9.0 in 2024, with an average of 134 institutional investors participating in research [6] Group 7 - The market response has been positive, with an average stock price increase of 77.2% for the 471 "dual improvement" companies from February 2024 to November 2025, outperforming the Shenzhen Component Index [7] - The total market capitalization of these companies reached 21.2 trillion yuan by November 2025, an increase of 8.1 trillion yuan since the initiative began, representing 50% of the total market capitalization of the Shenzhen market [7] - The number of companies with market capitalizations exceeding 100 billion yuan increased by 80, while those exceeding 1 trillion yuan increased by 21 since the initiative's launch [7]

Group 1 - The CRO sector is under pressure, with notable declines in stock prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kylin Pharmaceutical down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1] - The revised U.S. Biodefense Act was passed in the Senate with a vote of 77 to 20 and is set to be signed into law by the President, marking a significant legislative step [1] - The Biodefense Act has been a key factor in suppressing the valuation of the CXO sector over the past two years, but the final version is considered relatively moderate compared to the initial draft, as it does not specifically name companies [1] Group 2 - With the Federal Reserve entering a rate-cutting phase, there is potential for marginal improvement in global biopharmaceutical investment and financing [1] - The implementation of the Biodefense Act is expected to lead to a dual recovery in both performance and valuation for the CXO sector [1]

Group 1 - The CRO sector is under pressure, with notable declines in stock prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kylin Pharmaceutical down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1][1][1] - The revised U.S. Biodefense Law, part of the 2026 National Defense Authorization Act (NDAA), has passed the Senate with a vote of 77 to 20 and is expected to be signed by the President, completing the legislative process [1][1][1] - According to Cinda Securities, the Biodefense Law has been a significant factor in suppressing the valuation of the CXO sector over the past two years, but the final version is relatively moderate compared to the initial draft, as it does not specifically name companies [1][1][1] Group 2 - With the Federal Reserve entering a rate-cutting cycle, global biopharmaceutical investment and financing are expected to improve marginally [1][1][1] - The implementation of the Biodefense Law is anticipated to lead to a dual recovery in both performance and valuation for the CXO sector [1][1][1]